{"_id":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICA4PD19YwLDA","lastupdate":"2024-02-06T00:00:00.000Z","update_date":"2024-02-06T00:00:00.000Z","lastModified":"Oct 21, 2025","active":1,"confidence_score":100,"confidence_score_reason":"markets","urlname":"minovia-therapeutics","minimal_profile":null,"status":"Public","fullstatus":"Public on NASDAQ on Jun, 2025;","acquired":0,"hide_reason":null,"hide_reason_data":null,"hide_reasons":[{"id":"8257rxn4P8EFQOmS5hAAauHyYMhhxrA5u6yWX4XUShpybX3AMNo3Y9","reason":"Pending approval - External entity"},{"id":"aOIaOiiqfpA8UMw6VCTh8ueRmkG3lzDy1NGqEOaJbe11OrCzMTCCd6","reason":"The company is a service provider"},{"id":"ddgjKuc3GgH8E5UehSVJviRl471BCajL1plO8HtGoOojy2NivYqQ7x","reason":"Owner asked to delete"},{"id":"EjOKM211H1ira9J63oaGPuUxvr7Oba55TZo3NWsFO5uhbNu7o4x4zD","reason":"The company is not Israeli"},{"id":"J7fQJtnT3GdWWSE3MD8rzaW65LJ4jEIKxSZnneQiReONdZjG3zIqWe","reason":"Owner asked to hide in the meantime"},{"id":"NxlAC3ReFb5ksiYNLp2FnUyluoJzwRCYfcF7xpTZaPM53SdWQ5kv0B","reason":"Pending approval"},{"id":"RhC1tlwXzioK0MfzBII3H2wepEfQOfKVktmdwqeqTJjGi3ZaBWUqZo","reason":"The company is not innovative"},{"id":"S0Ed46vNI6vZYVxLedANWGjas23K6hY0QdsCtiGYL7lshqIEdLV3sA","reason":"The company ceased operations in Israel"},{"id":"VTANq7bEvlsEcPjp0ghelXfShaCosgndONGjgU730aAOxXtaDIF5j3","reason":"This is a product of an existing company"}],"type":"Startup","logokey":"$oMjYEagIne9f6gCE6HhBSTPCt5kHNArWUHh7bCtwG5cxteXYeiITxi.png","name":"Minovia Therapeutics","oneliner":"Mitochondrial Augmentation Cell-therapy Platform","registrar":"514704485","website":"https://minoviatx.com","careerspage":"https://minoviatx.com/careers","founded_month":12,"founded_year":2011,"formernames":[],"sociallinks":{"twitter":"https://twitter.com/minoviatx","youtube":"https://www.youtube.com/channel/UCL3q1kF6qdinl3xb0Eos9VA","facebook":"","linkedin":"https://www.linkedin.com/company/40691057","instagram":""},"social":["https://www.youtube.com/channel/UCL3q1kF6qdinl3xb0Eos9VA","https://www.linkedin.com/company/40691057","https://twitter.com/minoviatx"],"flattenedsociallinks":"https://www.youtube.com/channel/UCL3q1kF6qdinl3xb0Eos9VA|https://www.linkedin.com/company/40691057|https://twitter.com/minoviatx","apps":{"appstore":"","googleplay":""},"is_claimed_by_owner":null,"employees":"11-50","employees_exact":26,"patent":1,"raised":28350000,"stage":"Public","public_stage":"Public","primary_sector_key":"agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","primary_sector":"Health Tech & Life Sciences","alternativenames":["Minovia"],"about":"Minovia Therapeutics treats mitochondrial diseases through cell therapy using its Mitochondrial Augmentation Therapy (MAT) platform. The companys initial clinical focus is on rare mitochondrial diseases for which there are no approved treatments. \n\nThe company developed a cell therapy approach to treat a broad range of indications generated by a mitochondrial dysfunction. Using its proprietary Mitochondrial Augmentation Technology (MAT), designed to be a robust therapeutic platform combining personalized mitochondrial cell therapy and scalable manufacturing processes, Minovia is advancing breakthrough therapies for patients with mitochondrial dysfunction, caused by disease as well as during aging.\n\nMinovia is currently conducting a phase 1/2 clinical trial in patients with Pearson Syndrome.","climatetech_description":null,"is_climatetech_relevant":null,"phone":"+972747039954","country":null,"address":{"israeli":[{"id":"0bad68d3-50ca-4f7c-b9e4-10690ac6e7fb","city":" ","type":null,"address":"HaSadna 3, Tirat Carmel, Israel","placeid":null,"notactive":0,"openeddate":null,"registrarid":null,"firstrdcenter":0,"registrarname":null}],"officesabroad":[{"id":"3a2fb74b-afd9-4387-ac49-b1728819a052","city":"Cambridge","address":"Cambridge, Massachusetts, USA","country":"United States","placeid":null}]},"headquarter_address":null,"district":null,"news":[{"id":"TsCvjMVPAmZ3ey0w7rcsoMc5qLgVm63g1zaFnnGOYkUJjyRTqOCkAM","date":"Jun 24, 2025","link":"https://www.globenewswire.com/news-release/2025/06/25/3105093/0/en/Minovia-Therapeutics-Ltd-and-Launch-One-Acquisition-Corp-Announce-Proposed-Business-Combination-to-Create-Nasdaq-Listed-Mitochondrial-Therapy-Company-in-1-Trillion-Mitochondrial-an.html","source":"www.globenewswire.com","visible":1,"analysis":{"tags":"SPAC","round":null,"company":"Minovia Therapeutics Ltd.","layoffs":null,"summary":"Minovia Therapeutics Ltd., a clinical-stage biotechnology company, has entered into a definitive business combination agreement with Launch One Acquisition Corp., a special purpose acquisition company. This transaction will create a publicly traded entity focused on developing and commercializing Mitochondrial Augmentation Technology (MAT) to address diseases driven by mitochondrial dysfunction. The business combination is expected to close in the fourth quarter of 2025, providing Minovia with additional capital to accelerate its growth and development pipeline. The transaction assigns Minovia a pre-money equity valuation of $180 million, with additional PIPE investments anticipated. Minovias lead product, MNV-201, is in Phase 2 trials for Pearson Syndrome and has received FDA Fast Track Designation.","partners":null,"customers":null,"eventType":"SPAC","investors":["Launch One Acquisition Corp."],"confidence":9,"key_topics":["Mitochondrial therapy","Business combination","Longevity market","Clinical trials","FDA designation"],"date_of_event":"June 25, 2025","product_stage":"clinical trial","investment_date":null,"acquired_company":null,"valuation_amount":"$180 million","impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Public Trading","PIPE/PO","Investment"],"acquisition_amount":null,"FDA approved/pending approval":"pending approval","AI technology developing/using":null,"structuredIssuesShow":"#Public Trading  #PIPE/PO  #Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"3GWo28SHM465NRKgwwWDV5HgRpXSaaPK6Hp8GgDuvNVlTJK4iYusDO","news_summary":"Minovia Therapeutics Ltd. and Launch One Acquisition Corp. Announce Proposed Business Combination to Create Nasdaq-Listed Mitochondrial Therapy Company in $1 Trillion+ Mitochondrial and Longevity Markets","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"WrtrWtFJAVvuCSiIkScQseOah1Eo48DzR0CteifImQltc8UAXEeBTw","date":"Apr 2, 2025","link":"https://www.globenewswire.com/news-release/2025/04/03/3055005/0/en/Minovia-Therapeutics-Announces-FDA-Clearance-of-Second-IND-Application-for-a-Phase-II-Clinical-Trial-of-Lead-Product-MNV-201-in-Pearson-Syndrome.html","source":"www.globenewswire.com","visible":1,"analysis":{"tags":"FDA clearance","round":null,"company":"Minovia Therapeutics Ltd","layoffs":null,"summary":"Minovia Therapeutics Ltd, a clinical-stage biopharmaceutical company, has announced that the FDA has cleared its second Investigational New Drug (IND) application for MNV-201, a mitochondrial cell therapy product. This clearance allows Minovia to initiate a Phase II clinical trial for pediatric patients with Pearson Syndrome, a severe mitochondrial disease. The trial aims to evaluate the safety and efficacy of MNV-201, focusing on improving growth and quality of life. The FDAs clearance marks a significant milestone for Minovia, enabling them to advance their allogeneic mitochondrial therapy approach. The study will enroll additional patients and is expected to provide insights into the potential benefits of MNV-201 for this patient population.","partners":null,"customers":null,"eventType":null,"investors":null,"confidence":10,"key_topics":["MNV-201","Pearson Syndrome","FDA clearance","clinical trial","mitochondrial therapy"],"date_of_event":"April 03, 2025","product_stage":"clinical trial","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Product Stage","FDA approved/pending approval"],"acquisition_amount":null,"FDA approved/pending approval":"pending approval","AI technology developing/using":null,"structuredIssuesShow":"#Product Stage  #FDA approved/pending approval","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"kqrztgZP5t37btUptrYYGV9f0emEYs357XR3oRnV4OipBJVMVGt1Og","news_summary":"Minovia Therapeutics Announces FDA Clearance of Second IND Application, for a Phase II Clinical Trial of Lead Product MNV-201 in Pearson Syndrome","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"664q05TUVZhBxbbdFaD5EMqbIng5vYJ71DobKaHINTFWaPPD5PRdbG","date":"Feb 1, 2023","link":"https://www.israel21c.org/new-cell-therapy-may-be-key-to-curing-disease/","source":"www.israel21c.org","visible":1,"analysis":{"tags":["mitochondrial augmentation therapy","rare mitochondrial diseases","cell therapy","clinical trials","collaborations"],"company":"Minovia Therapeutics","layoffs":null,"summary":"Minovia Therapeutics, an Israeli company, is developing mitochondrial augmentation therapy (MAT) to treat rare mitochondrial diseases. The therapy involves enriching hematopoietic stem cells with healthy mitochondria and injecting them back into patients. The company has conducted successful trials on children with Pearson syndrome, a bone marrow disorder. The children showed improvement in aerobic function, weight gain, and strength. Minovia is now developing an off-the-shelf product using mitochondria from donated placentas. The first indication for the product is still Pearson syndrome, but the company plans to expand to other indications. Minovia intends to collaborate with big pharma companies and has already partnered with Astellas Pharma. The company has received investments totaling nearly $30 million and holds 70 patents. It has 46 employees, mostly female.","partners":["Astellas Pharma"],"customers":null,"investors":"Astellas Pharma","confidence":9,"key_topics":["Mitochondrial augmentation therapy","Pearson syndrome","Placenta-derived mitochondria","Clinical trials","Collaborations"],"date_of_event":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Customers","Partners","Investment","Management Changes"],"acquisition_amount":null,"structuredIssuesShow":"#Customers  #Partners  #Investment  #Management Changes","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"DQ9uzky08na7TQrlJHz3rZX8FaUt0pnkgl8KUmKV7YB0wh8gNYOgwr","news_summary":"New cell therapy may be key to curing disease - ISRAEL21c","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"I35tICjToDw6ZluItmVlrqKED4TRL6z2Ur21Rko2pmsom4q2Oem6Hz","date":"Oct 1, 2021","link":"https://www.businesswire.com/news/home/20211001005050/en/Minovia-Therapeutics-Announces-Data-from-Preclinical-Studies-Demonstrating-that-Mitochondrial-Augmentation-of-CD34-cells-Confers-Functional-Benefit-and-that-Mitochondrial-Transfer-Occurs-Between-Hematopoietic-Cells-In-Vivo","source":"www.businesswire.com","visible":1,"analysis":{"entityGrowthIconPath":"none;"},"sentiment":null,"analysisId":"BfUOoWdKAkXArOZqX4mQ3tZRgSnY2u7WD0dTsMRnn6xBUI6n2NBeHM","news_summary":"Minovia Therapeutics Announces Data from Preclinical Studies Demonstrating that Mitochondrial Augmentation of CD34+ cells Confers Functional Benefit and that Mitochondrial Transfer Occurs Between Hematopoietic Cells In Vivo","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"983fa71b-eae6-4ddf-8792-44c7b9873fe1","date":"Jul 30, 2021","link":"https://www.businesswire.com/news/home/20210730005049/en/Astellas-and-Minovia-Therapeutics-Announce-Strategic-Collaboration-for-Novel-Mitochondrial-Cell-Therapy-Programs","source":"www.businesswire.com","visible":1,"analysis":{"tags":"Partnership, Investment","company":"Minovia Therapeutics, Ltd. and Astellas Pharma Inc.","layoffs":"Not mentioned","summary":"Minovia Therapeutics and Astellas Pharma have announced a global strategic collaboration and license agreement for the research, development, and commercialization of novel cell therapy programs for diseases caused by mitochondrial dysfunction. The partnership aims to accelerate the creation of allogeneic mitochondrial cell therapy programs, with the two companies jointly researching cell therapy program candidates. Under the terms of the agreement, Minovia will receive an upfront cash payment of $20M USD from Astellas. If Astellas develops and commercializes product candidates for diseases caused by mitochondrial dysfunction, Minovia could receive up to $420M USD per product in future development, regulatory and commercial milestone payments from Astellas.","partners":"Astellas Pharma Inc.","customers":"Not mentioned","investors":"Astellas Pharma Inc.","confidence":9,"key_topics":["Strategic Collaboration","License Agreement","Cell Therapy","Mitochondrial Dysfunction","Investment"],"date_of_event":"Not mentioned","valuation_amount":"Not mentioned","impact_on_company":"growth-positive","investment_amount":"$20M USD upfront, up to $420M USD in future milestone payments","structured_issues":["Partners","Investment"],"acquisition_amount":"Not mentioned","structuredIssuesShow":"#Partners  #Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"L548ZEyHgTRGXr2H2uK6KWU9nxRNpMjAc470EELi40RzIVNT1bV4yj","news_summary":"Astellas and Minovia Therapeutics Announce Strategic Collaboration for Novel Mitochondrial Cell Therapy Programs","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"bce6deaf-3504-4e21-be8d-7c8f6727b433","date":"Mar 12, 2021","link":"https://www.fiercebiotech.com/biotech/mitochondrial-biotech-minovia-therapeutics-nabs-biopharma-veteran-alan-jacobs-as-new-chief","source":"www.fiercebiotech.com","visible":1,"analysis":{"tags":"Legal","company":"Questex LLC","layoffs":"N/A","summary":"The article discusses the terms of use and privacy policy of Questex LLC.","partners":"N/A","customers":"N/A","investors":"N/A","confidence":8,"key_topics":["Questex LLC","Terms of use","Privacy Policy"],"date_of_event":"N/A","valuation_amount":"N/A","impact_on_company":"N/A","investment_amount":"N/A","structured_issues":[],"acquisition_amount":"N/A","entityGrowthIconPath":"none;"},"sentiment":"N/A","analysisId":"ziKTw2rhpxF0Pltn1NHGwCpe5sRLdHqUrSOOwhxxAoMntLK49HfoqV","news_summary":"Mitochondrial biotech Minovia Therapeutics nabs biopharma veteran Jacobs as new chief medical officer","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"9f2d6f7f-ec65-4154-82d6-c704bda883e8","date":"Nov 23, 2020","link":"https://www.businesswire.com/news/home/20201123005571/en/Minovia-Therapeutics-Announces-Manufacturing-Partnership-with-BioSpherix-and-Appoints-David-O%E2%80%99Donnell-as-Global-Head-of-Manufacturing-and-Supply-Chain","source":"www.businesswire.com","visible":1,"analysis":{"entityGrowthIconPath":"none;"},"sentiment":null,"analysisId":"zlR26aiKxexfnO1Ga8pSmaR5Sz5Ok0FnlMymaQUEAPein2u1x2DFJV","news_summary":"Minovia Therapeutics Announces Manufacturing Partnership with BioSpherix and Appoints David O'Donnell as Global Head of Manufacturing and Supply Chain","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"6f2cb89b-a6d1-4361-aa93-693e9444ee9b","date":"Nov 9, 2020","link":"https://www.businesswire.com/news/home/20201109005274/en/Minovia-Therapeutics-to-Participate-at-Upcoming-Credit-Suisse-Healthcare-Conference-on-November-12th","source":"www.businesswire.com","visible":1,"analysis":{"entityGrowthIconPath":"none;"},"sentiment":null,"analysisId":"FNLWHGErW9QdzKuvdwWZHXwBM2Eghw9kemBU8glBruL25n8RYemZKs","news_summary":"Minovia Therapeutics to Participate at Upcoming Credit Suisse Healthcare Conference on November 12th","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"3812467e-7ea1-469a-95e5-0b0eaed5b772","date":"Jun 15, 2020","link":"https://bostonrealestatetimes.com/minovia-therapeutics-leases-4600-sf-in-woburn/","source":"bostonrealestatetimes.com","visible":1,"analysis":{"tags":"expansion","company":"Minovia Therapeutics","layoffs":null,"summary":"Minovia Therapeutics, an international life sciences firm, is expanding its U.S. operations by opening a 4,600-square-foot facility in Woburns technology cluster. The company, which specializes in developing cell therapy for rare mitochondrial diseases, will commence its GMP manufacturing at the new facility. The location and buildout of the space are ideal for Minovias operations. The expansion signifies growth for the company.","partners":null,"customers":null,"investors":null,"confidence":8,"key_topics":["expansion","cell therapy","rare mitochondrial diseases","GMP manufacturing","new facility"],"date_of_event":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Expand"],"acquisition_amount":null,"structuredIssuesShow":"#Expand","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"ysoVEAeH7oCO9z1fPNAyaDW5HTDNE82M5TuFdeKycdyRuD18KsiWQL","news_summary":"Minovia Therapeutics Leases 4,600 SF in Woburn - Boston Real Estate Times","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"217cdc88-0ec0-4e79-89a0-70276a74489a","date":"Jul 16, 2019","link":"https://www.biospace.com/article/new-hope-for-rare-mitochondrial-diseases-an-interview-with-minovia-therapeutics-natalie-yivgi-ohana/","source":"www.biospace.com","visible":1,"analysis":{"tags":["mitochondrial diseases","clinical trial","cell therapy","rare diseases"],"company":"Minovia Therapeutics","layoffs":null,"summary":"Minovia Therapeutics has dosed the first patient in a Phase I/II clinical trial for Pearson syndrome, a rare mitochondrial disease. The company is using its Mitochondrial Augmentation Therapy (MAT) platform, which aims to increase the level of normal mitochondrial DNA using autologous stem cells enriched with normal mitochondria. The trial will evaluate the safety and clinical effects of the companys autologous CD34+ cells enriched with blood-derived mitochondria in pediatric patients. Minovia is also planning to open an office in Cambridge, Massachusetts and hire 20 employees by the end of 2020. The company is focused on partnering with academic and medical institutions and developing new therapies for mitochondrial diseases.","partners":null,"customers":null,"investors":null,"confidence":8,"key_topics":["Mitochondrial diseases","Clinical trial","Cell therapy","Rare diseases","Genetic diseases"],"date_of_event":"June 2020","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Customers"],"acquisition_amount":null,"structuredIssuesShow":"#Customers","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"zKiEWrvgIy9fe1ymhhcJNDgzzkzY1zZa6MPuAqGed606Zzf7pTfxVI","news_summary":"New Hope for Rare Mitochondrial Diseases: An Interview With Minovia Therapeutics' Natalie Yivgi Ohana  BioSpace","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"49f51b3b-4b2d-46e2-8525-7bd7b3dce8d6","date":"Jun 26, 2019","link":"https://www.biospace.com/article/releases/minovia-announces-dosing-of-patient-in-first-mitochondrial-cell-therapy-trial-for-the-treatment-of-pearson-syndrome/","source":"www.biospace.com","visible":1,"analysis":{"tags":"clinical trial","company":"Minovia Therapeutics","layoffs":null,"summary":"Minovia Therapeutics has announced the dosing of the first patient in a Phase I/II clinical trial of its Mitochondrial Augmentation Therapy (MAT) for the treatment of Pearson syndrome. The trial, which is the first ever mitochondrial cell therapy trial for a mitochondrial disease, has been granted Fast-Track, Orphan Drug, and Rare Pediatric Disease designations by the FDA. Minovia will present case studies of patients treated with MAT at a conference in June. The company is also opening a U.S. operation in Cambridge, Massachusetts, to expand its clinical and research collaborations. John Cox has been appointed as chairman of the board. Pearson syndrome is a rare pediatric mitochondrial disease caused by a deletion in mitochondrial DNA.","partners":null,"customers":null,"investors":null,"confidence":9,"key_topics":["Mitochondrial Augmentation Therapy","Pearson syndrome","clinical trial","mitochondrial diseases","MAT platform"],"date_of_event":"June 26, 2019","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Customers"],"acquisition_amount":null,"structuredIssuesShow":"#Customers","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"fchx6BR3THrOMkUVPxJBWLI0Th4bOUbUIpGtzcbIRxP7q5CVCxGECj","news_summary":"Minovia Announces Dosing of Patient in First Mitochondrial Cell Therapy Trial for the Treatment of Pearson Syndrome  BioSpace","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"}],"newsNumber":12,"techcommunityinvolvement":null,"mediagallery":[{"id":"e24ed81d-91a1-4744-8a23-190951f8ad84","timestamp":"2020-11-26 15:31:53.000000","resources_type":2,"resources_title":"","resources_file_name":"uWMGbn0JMkQ","alt":"","imageurl":"https://img.youtube.com/vi/uWMGbn0JMkQ/0.jpg","url":"http://youtu.be/uWMGbn0JMkQ"}],"tags":["pediatrics","seniors","autoimmune-diseases","biotechnology","cell-therapy","rare-diseases","pharma-companies","children","medical-technologies"],"classificationIDs":["agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4JvZ7vMIDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4PuD2a4JDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Iety_cIDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA"],"technologysuccessstory":null,"usecases":[],"businessmodels":["B2B"],"productstage":"Clinical Trial","products":["Mitochondrial Augmentation Therapy"],"geomarkets":["United States","Europe","Israel"],"targetmarkets":[],"marketcapital":null,"marketcapitaldate":null,"funding":{"investors":3,"lastfunding":"$350K","totalrounds":5,"fundingstage":"Public","totalfunding":"$28.35M","publicinvestors":3,"lastpublicfunding":350000,"totalpublicrounds":5,"totalpublicfunding":28350000},"team":[{"name":"Natalie Yivgi-Ohana","email":"natalie@minovia.co.il","phone":"0545833727","gender":"Female","userid":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICAoKmc5p4KDA","bounced":true,"claimed":0,"founder":1,"urlname":"natalie-yivgi-ohana-1","visible":1,"memberid":"agxzfmlsbGlzdHNpdGVyFwsSCk5ld19NZW1iZXIYgIDgsI3JtQsM","position":"CEO & Co-founder","last_name":"Yivgi-Ohana","claimtoken":"F2Pb0Oz7aBekJ1tE4AcnVXhmgKr54tbTcGlQrtJwZubE7etOMLBWjR","first_name":"Natalie","picturekey":"$Tptef1asTzpPsioMhLqhInDBk338HUthWC0XlAUdSScoplhBhPZTpv","claimeddate":null,"linkedinurl":"https://www.linkedin.com/in/natalie-yivgi-ohana-02194b31/","unsubscribed":false,"is_activeuser":1,"additionalemail":"natalie@minoviatx.com","claimedemaildate":"2024-02-06 12:35:26.000000","initials":"","pictureurl":"https://storage.googleapis.com/clean-finder-353810/$Tptef1asTzpPsioMhLqhInDBk338HUthWC0XlAUdSScoplhBhPZTpv","linkedin-display":"flex","teammembertagclass":"none","teammembertagcontent":"","channelId":"","visibilityClassName":"","visibilityTooltip":""},{"name":"Noa Sher","email":"noa@minoviatx.com","phone":"","gender":"Male","userid":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICA4Ij516sLDA","bounced":false,"claimed":0,"founder":0,"urlname":"noa-sher","visible":1,"memberid":"agxzfmlsbGlzdHNpdGVyFwsSCk5ld19NZW1iZXIYgIDgqPDelwkM","position":"Chief Scientist","last_name":"Sher","claimtoken":"3cEdRD91KLHOFbs5lmCyEVufq8moIZs1uhfY59qFycf3A0AYPW3GTn","first_name":"Noa","picturekey":null,"claimeddate":null,"linkedinurl":"https://www.linkedin.com/in/noa-sher-9755985/","unsubscribed":false,"is_activeuser":1,"additionalemail":"","claimedemaildate":"2024-02-06 12:35:29.000000","initials":"NS","pictureurl":"/assets/empty-state.svg","linkedin-display":"flex","teammembertagclass":"connect","teammembertagcontent":"Connect","channelId":"","visibilityClassName":"","visibilityTooltip":""},{"name":"Nadav  Eshkol","email":"nadav@minoviatx.com","phone":"","gender":"Male","userid":"BIycUOEFCTmqS9VRhSoZAvIi2nlxZBWqLCI47UM1mJibSNKYRjUvvM","bounced":false,"claimed":null,"founder":0,"urlname":"nadav-eshkol","visible":1,"memberid":"LgdU10mO1owtTopTanL2xb8I0fyJC0va9xciWgP5fqDsN6Enkgwgiu","position":"VP Operations","last_name":"Eshkol","claimtoken":"Jf1ICuRY3ROGPRdb5r4mr6pWS0qx291bENnUBmOWZZ4lVcg6D3MvDH","first_name":"Nadav ","picturekey":null,"claimeddate":null,"linkedinurl":"https://www.linkedin.com/in/nadav-eshkol-2230286a/","unsubscribed":false,"is_activeuser":0,"additionalemail":"","claimedemaildate":"2024-02-06 12:37:17.000000","initials":"NE","pictureurl":"/assets/empty-state.svg","linkedin-display":"flex","teammembertagclass":"none","teammembertagcontent":"","channelId":"","visibilityClassName":"","visibilityTooltip":""}],"description_edited":1,"tag_line_edited":1,"sector":"Pharmaceuticals","sectorverify":{"id":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICAoPW8rMQKDA","fullname":"Lena Rogovina"},"biverify":{"id":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICAoNqyo8cLDA","fullname":"Yotam Maman"},"biverifydate":"2019-12-01T00:00:00.000Z","crunchbaseid":"minovia-therapeutics","lastupdator":"Yanina Wainscheinker","lastupdator_email":"yanina.wainscheinker@sncentral.org","creator":"Jenny Sotnik-Talisman","creator_email":"genys30@yahoo.com","createdate":"2019-03-18T00:00:00.000Z","biverification":"Yotam Maman","sectorverification":"Lena Rogovina","affiliatedOrganizations":null,"timeline":[{"id":"mRsYpjKAEScOm9iEISSUC6ttu040agSa1aXCCPmlNnr4jgk2VXr2zw","date":"Aug 2025","amount":"$350K","source":"","eventtype":"GrantEvent","granttype":0,"investment":[{"name":null,"type":null,"amount":null,"hidden":false,"country":"Israel","fullurl":null,"logokey":null,"tagline":null,"urlname":null,"isisraeli":null,"investorid":null,"fundingtype":"Angel","leadpartner":null,"investmentid":"8CsbpOCC0TMnbyjXLrfD3Sm1MWO6oYd8dhnNk45OqsckPAnbDNdkNZ","fundingsubtype":null,"investorislead":0,"amountvisibility":"Public","isextensionround":null,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"/assets/empty-state.svg","investmentVisibilityClassName":"","investmentVisibilityTooltip":"","leadcaption":"","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":null,"isjointventuregrant":0,"style":"","hiddenCompanyTooltip":"","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","sectionname":"Non-Equity Funding","isgrant":true,"isicoevent":false,"amountnumber":350000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"rUV7ZSvfkicTiVe2steA94DZ87RBdPEuZ6RJBSgsH3uapO3SZr5SbH","date":"Jun 2025","amount":"Undisclosed","source":"https://www.globenewswire.com/news-release/2025/06/25/3105093/0/en/Minovia-Therapeutics-Ltd-and-Launch-One-Acquisition-Corp-Announce-Proposed-Business-Combination-to-Create-Nasdaq-Listed-Mitochondrial-Therapy-Company-in-1-Trillion-Mitochondrial-an.html","ticker":"MITO","eventtype":"ReverseMergerEvent","valuation":"Undisclosed","investment":[],"capitalraised":"Undisclosed","stockexchange":"NASDAQ","eventvisibility":"Public","amountvisibility":null,"fundingvisibility":null,"stockexchange_key":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCIutD_CQw","stockexchange_logokey":"$AU2PTNC6m8YQhSAZinm36kCeLZigl0lwDvuFvOK4ns8LMZtmlmhlUB","acquiredcompany_reverse":"Launch One Acquisition Corp.","acquiredcompany_reverse_id":"FkZ2yWAL8FKuEHo1RLvhC6KyMnqszi0y24az16h7Kmkdd7y0ppkHdU","acquiredcompany_reverse_type":"Multinational","acquiredcompany_reverse_hidden":true,"acquiredcompany_reverse_fullurl":"/mnc_page/launch-one-acquisition-corp","acquiredcompany_reverse_logokey":null,"acquiredcompany_reverse_urlname":"/mnc_page/launch-one-acquisition-corp","acquiredcompany_reverse_homepage":"https://launchoneacquisitioncorp.com/","style":"","hiddenCompanyTooltip":"","stockexchange_logourl":"https://storage.googleapis.com/clean-finder-353810/$AU2PTNC6m8YQhSAZinm36kCeLZigl0lwDvuFvOK4ns8LMZtmlmhlUB","acquiredcompany_reverse_logourl":"/assets/empty-state.svg","exit_label":"EXIT","po_label":"Initial Public Offering","acquireddesc":"Was acquired by","sectionname":"Public Offerings & Exit","amountnumber":null,"capitalraisednumber":null,"valuationnumber":null},{"id":"MwhHJBx1RkZ8iB0D8YtX1aqDL5J5rEUhjPsZoIi18nig7TxxSidXGH","date":"Jun 2025","amount":"$18M","source":"https://www.globenewswire.com/news-release/2025/06/25/3105093/0/en/Minovia-Therapeutics-Ltd-and-Launch-One-Acquisition-Corp-Announce-Proposed-Business-Combination-to-Create-Nasdaq-Listed-Mitochondrial-Therapy-Company-in-1-Trillion-Mitochondrial-an.html","eventtype":"FundingRoundEvent","investment":[],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"PIPE","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":18000000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"eGLnCx8hvN82Pir0zL2n2hSI1M3FKW2qXbhXFjTQoTGdpVysZjDyku","date":"Jan 2025","amount":"Undisclosed","source":"4t ventures silent round","eventtype":"FundingRoundEvent","investment":[{"name":"4T Ventures","type":"Investor","amount":null,"hidden":false,"country":"Israel","fullurl":"/investor_page/4t-ventures","logokey":"$Vny0BIxgCa4Aj6t47drgTl7ZX5qvoqniNaWDz120iZvym5H2YUaYZt.png","tagline":null,"urlname":"/investor_page/4t-ventures","isisraeli":1,"investorid":"FeBlmwKKnvTF4Drzk4f4hKCGJUXjZRGDk4uWjk6HlcgYnFnleQwzup","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"afa6TBMyjlETkEqSdNBvFHThzSy044YwwGQYyoJwFiXoGbojHxYUVL","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$Vny0BIxgCa4Aj6t47drgTl7ZX5qvoqniNaWDz120iZvym5H2YUaYZt.png","leadcaption":"","followupcaption":""}],"eventvisibility":"Public","amountvisibility":null,"fundingvisibility":"Public","fundingtypefundingtype":"Seed","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":null,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"lFezZ419BoPcsrEOjuwK2H2FCRYpOz9WJPOaHHfMTHTitWu2GlOup0","date":"Feb 2021","amount":"Undisclosed","source":"https://eithealth.eu/news-article/eit-health-start-up-collaboration-astellas/","eventtype":"FundingRoundEvent","investment":[{"name":"eit health","type":"Accelerator","amount":null,"hidden":true,"country":"Germany","fullurl":"/program_page/eit-health-1","logokey":"$dIzwIswG6RskoZFZuZopSgKuR43bBmTTgee6RojZBqOaMRB8DSX6cp.png","tagline":"Accelerator","urlname":"/program_page/eit-health-1","isisraeli":0,"investorid":"sWm2IpxMHP3nh0WwFLOxQbRb6CxTwcu2kBtWkvK2w8HuBe5heYRow2","fundingtype":"General","leadpartner":null,"investmentid":"KUdeUBS90RVNBRsCryV8WWmlbtO1q9QCIpu8Rn5XCFmKQeiiND9hY8","fundingsubtype":"General","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$dIzwIswG6RskoZFZuZopSgKuR43bBmTTgee6RojZBqOaMRB8DSX6cp.png","leadcaption":"","followupcaption":""}],"eventvisibility":"Public","amountvisibility":null,"fundingvisibility":"Public","fundingtypefundingtype":"Undisclosed Round","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":null,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"FWaCZyLFTMGCZhMWkFidOfNb8HIkTy76YFatVNpr7VAcNafFP3WCDt","date":"Dec 2018","amount":"$10M","source":"https://www.yozma.com/portfolio","eventtype":"FundingRoundEvent","investment":[{"name":"The Yozma Group","type":"Investor","amount":null,"hidden":false,"country":"Israel","fullurl":"/investor_page/yozma-group","logokey":"$wVMapdgnKlFiqgrIKRf9wjNDUkTpRoZlYd4H0PB4CxZ9ctDMydVRD4","tagline":null,"urlname":"/investor_page/yozma-group","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgKnapokKDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"OCLnq0Ka9oKZSSKOZz5GrkOf7RZ6uYFJZrEyZcHtQ65f8Xricny7g5","fundingsubtype":"VC and Private Equity","investorislead":1,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$wVMapdgnKlFiqgrIKRf9wjNDUkTpRoZlYd4H0PB4CxZ9ctDMydVRD4","leadcaption":"Lead ","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"Seed","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":10000000,"capitalraised":"Undisclosed","valuation":"Undisclosed"}],"investmentstage":[],"exits":[],"investments":[],"portfolio":[],"funds":[],"founded":"12/2011","databases":[],"sharedspaces":[],"utilities":[],"contributors":[],"employeesworldwide":"","fundingtype":"Startup","parsedName":"Minovia Therapeutics","logourl":"https://storage.googleapis.com/clean-finder-353810/$oMjYEagIne9f6gCE6HhBSTPCt5kHNArWUHh7bCtwG5cxteXYeiITxi.png","oglogourl":"https://storage.googleapis.com/clean-finder-353810/$oMjYEagIne9f6gCE6HhBSTPCt5kHNArWUHh7bCtwG5cxteXYeiITxi.png","seoabout":"Minovia Therapeutics treats mitochondrial diseases through cell therapy using its Mitochondrial Augmentation Therapy (MAT) platform. The companys initial c...","seoTitle":"Israeli Startup","solutions":[],"teamMembersNumber":3,"primarySector":"Health Tech & Life Sciences","primary-sector-display":"block","classifications":[{"depth":0,"name":"Sector","queryString":"sectorclassification=undefined","classificationName":"sectorclassification"},{"depth":1,"name":"Health Tech & Life Sciences","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","classificationName":"sectorclassification"},{"depth":2,"name":"Pharma & Medical Biotechnology","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA","classificationName":"sectorclassification"},{"depth":3,"name":"Drugs Discovery & Development","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Iety_cIDA","classificationName":"sectorclassification"},{"depth":0,"name":"Core Technology","queryString":"coretechnology=undefined","classificationName":"coretechnology"},{"depth":1,"name":"Biologicals","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA","classificationName":"coretechnology"},{"depth":2,"name":"Cells","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4JvZ7vMIDA","classificationName":"coretechnology"},{"depth":0,"name":"Target Customer","queryString":"targetcustomer=undefined","classificationName":"targetcustomer"},{"depth":1,"name":"Healthcare & Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","classificationName":"targetcustomer"},{"depth":2,"name":"Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA","classificationName":"targetcustomer"},{"depth":3,"name":"Pharmaceuticals","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA","classificationName":"targetcustomer"},{"depth":2,"name":"Healthcare","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA","classificationName":"targetcustomer"},{"depth":3,"name":"Patients","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4PuD2a4JDA","classificationName":"targetcustomer"}],"classificationDelimited":["SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA>Pharmaceuticals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","TechnologyClassificationModel>Biologicals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA>Cells#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4JvZ7vMIDA","TechnologyClassificationModel>Biologicals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Healthcare#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA>Patients#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4PuD2a4JDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Healthcare#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA","SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA>Drugs Discovery & Development#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Iety_cIDA","SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA"],"classificationsViewModel":"|0:>SectorClassificationModel|1:>SectorClassificationModel/Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA|2:>SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA/Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA|3:>SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA/Drugs Discovery & Development#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Iety_cIDA|0:>IndustryClassificationModel|1:>IndustryClassificationModel/Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA|2:>IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA/Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA|3:>IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA/Pharmaceuticals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA|2:>IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA/Healthcare#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA|3:>IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Healthcare#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA/Patients#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4PuD2a4JDA|0:>TechnologyClassificationModel|1:>TechnologyClassificationModel/Biologicals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA|2:>TechnologyClassificationModel>Biologicals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA/Cells#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4JvZ7vMIDA|","classificationTrees":{"sector":[{"title":"Health Tech & Life Sciences","key":"0-0","path":"SectorClassificationModel>Health Tech & Life Sciences","children":[{"title":"Pharma & Medical Biotechnology","key":"0-0-0","path":"SectorClassificationModel>Health Tech & Life Sciences>Pharma & Medical Biotechnology","children":[{"title":"Drugs Discovery & Development","key":"0-0-0-0","path":"SectorClassificationModel>Health Tech & Life Sciences>Pharma & Medical Biotechnology>Drugs Discovery & Development"}]}]}],"targetCustomer":[{"title":"Healthcare & Life Sciences","key":"0-0","path":"IndustryClassificationModel>Healthcare & Life Sciences","children":[{"title":"Life Sciences","key":"0-0-0","path":"IndustryClassificationModel>Healthcare & Life Sciences>Life Sciences","children":[{"title":"Pharmaceuticals","key":"0-0-0-0","path":"IndustryClassificationModel>Healthcare & Life Sciences>Life Sciences>Pharmaceuticals"}]},{"title":"Healthcare","key":"0-0-1","path":"IndustryClassificationModel>Healthcare & Life Sciences>Healthcare","children":[{"title":"Patients","key":"0-0-1-0","path":"IndustryClassificationModel>Healthcare & Life Sciences>Healthcare>Patients"}]}]}],"coreTechnology":[{"title":"Biologicals","key":"0-0","path":"TechnologyClassificationModel>Biologicals","children":[{"title":"Cells","key":"0-0-0","path":"TechnologyClassificationModel>Biologicals>Cells"}]}]},"sectorClassifications":[{"depth":0,"name":"Sector","queryString":"sectorclassification=undefined","classificationName":"sectorclassification"},{"depth":1,"name":"Health Tech & Life Sciences","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","classificationName":"sectorclassification"},{"depth":2,"name":"Pharma & Medical Biotechnology","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA","classificationName":"sectorclassification"},{"depth":3,"name":"Drugs Discovery & Development","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Iety_cIDA","classificationName":"sectorclassification"}],"coreTechnologyClassifications":[{"depth":0,"name":"Core Technology","queryString":"coretechnology=undefined","classificationName":"coretechnology"},{"depth":1,"name":"Biologicals","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA","classificationName":"coretechnology"},{"depth":2,"name":"Cells","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4JvZ7vMIDA","classificationName":"coretechnology"}],"targetCustomerClassifications":[{"depth":0,"name":"Target Customer","queryString":"targetcustomer=undefined","classificationName":"targetcustomer"},{"depth":1,"name":"Healthcare & Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","classificationName":"targetcustomer"},{"depth":2,"name":"Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA","classificationName":"targetcustomer"},{"depth":3,"name":"Pharmaceuticals","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA","classificationName":"targetcustomer"},{"depth":2,"name":"Healthcare","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA","classificationName":"targetcustomer"},{"depth":3,"name":"Patients","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4PuD2a4JDA","classificationName":"targetcustomer"}],"classificationNames":{"sector":["Health Tech & Life Sciences","Pharma & Medical Biotechnology","Drugs Discovery & Development"],"coreTechnology":["Biologicals","Cells"],"targetCustomer":["Healthcare & Life Sciences","Life Sciences","Pharmaceuticals","Healthcare","Patients"]},"section":null,"sectionParams":"","queryParams":"","popup_claim_profile":"false","claimedBadge":"none","display":{"mainContact":"none","climateTag":"none","seeMoreSimilarCompanisDisplay":"none","similarCompaniesTitleFontSize":"3.2rem","similarCompaniesTitle":"Similar Companies","similar_companies":[]},"mainContact":{},"_eventview":{"publicoffering_exit":[{"id":"rUV7ZSvfkicTiVe2steA94DZ87RBdPEuZ6RJBSgsH3uapO3SZr5SbH","date":"Jun 2025","amount":"Undisclosed","source":"https://www.globenewswire.com/news-release/2025/06/25/3105093/0/en/Minovia-Therapeutics-Ltd-and-Launch-One-Acquisition-Corp-Announce-Proposed-Business-Combination-to-Create-Nasdaq-Listed-Mitochondrial-Therapy-Company-in-1-Trillion-Mitochondrial-an.html","ticker":"MITO","eventtype":"ReverseMergerEvent","valuation":"Undisclosed","investment":[],"capitalraised":"Undisclosed","stockexchange":"NASDAQ","eventvisibility":"Public","amountvisibility":null,"fundingvisibility":null,"stockexchange_key":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCIutD_CQw","stockexchange_logokey":"$AU2PTNC6m8YQhSAZinm36kCeLZigl0lwDvuFvOK4ns8LMZtmlmhlUB","acquiredcompany_reverse":"Launch One Acquisition Corp.","acquiredcompany_reverse_id":"FkZ2yWAL8FKuEHo1RLvhC6KyMnqszi0y24az16h7Kmkdd7y0ppkHdU","acquiredcompany_reverse_type":"Multinational","acquiredcompany_reverse_hidden":true,"acquiredcompany_reverse_fullurl":"/mnc_page/launch-one-acquisition-corp","acquiredcompany_reverse_logokey":null,"acquiredcompany_reverse_urlname":"/mnc_page/launch-one-acquisition-corp","acquiredcompany_reverse_homepage":"https://launchoneacquisitioncorp.com/","style":"","hiddenCompanyTooltip":"","stockexchange_logourl":"https://storage.googleapis.com/clean-finder-353810/$AU2PTNC6m8YQhSAZinm36kCeLZigl0lwDvuFvOK4ns8LMZtmlmhlUB","acquiredcompany_reverse_logourl":"/assets/empty-state.svg","exit_label":"EXIT","po_label":"Initial Public Offering","acquireddesc":"Was acquired by","sectionname":"Public Offerings & Exit","amountnumber":null,"capitalraisednumber":null,"valuationnumber":null}],"privateequityfunding":[{"id":"MwhHJBx1RkZ8iB0D8YtX1aqDL5J5rEUhjPsZoIi18nig7TxxSidXGH","date":"Jun 2025","amount":"$18M","source":"https://www.globenewswire.com/news-release/2025/06/25/3105093/0/en/Minovia-Therapeutics-Ltd-and-Launch-One-Acquisition-Corp-Announce-Proposed-Business-Combination-to-Create-Nasdaq-Listed-Mitochondrial-Therapy-Company-in-1-Trillion-Mitochondrial-an.html","eventtype":"FundingRoundEvent","investment":[],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"PIPE","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":18000000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"eGLnCx8hvN82Pir0zL2n2hSI1M3FKW2qXbhXFjTQoTGdpVysZjDyku","date":"Jan 2025","amount":"Undisclosed","source":"4t ventures silent round","eventtype":"FundingRoundEvent","investment":[{"name":"4T Ventures","type":"Investor","amount":null,"hidden":false,"country":"Israel","fullurl":"/investor_page/4t-ventures","logokey":"$Vny0BIxgCa4Aj6t47drgTl7ZX5qvoqniNaWDz120iZvym5H2YUaYZt.png","tagline":null,"urlname":"/investor_page/4t-ventures","isisraeli":1,"investorid":"FeBlmwKKnvTF4Drzk4f4hKCGJUXjZRGDk4uWjk6HlcgYnFnleQwzup","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"afa6TBMyjlETkEqSdNBvFHThzSy044YwwGQYyoJwFiXoGbojHxYUVL","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$Vny0BIxgCa4Aj6t47drgTl7ZX5qvoqniNaWDz120iZvym5H2YUaYZt.png","leadcaption":"","followupcaption":""}],"eventvisibility":"Public","amountvisibility":null,"fundingvisibility":"Public","fundingtypefundingtype":"Seed","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":null,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"lFezZ419BoPcsrEOjuwK2H2FCRYpOz9WJPOaHHfMTHTitWu2GlOup0","date":"Feb 2021","amount":"Undisclosed","source":"https://eithealth.eu/news-article/eit-health-start-up-collaboration-astellas/","eventtype":"FundingRoundEvent","investment":[{"name":"eit health","type":"Accelerator","amount":null,"hidden":true,"country":"Germany","fullurl":"/program_page/eit-health-1","logokey":"$dIzwIswG6RskoZFZuZopSgKuR43bBmTTgee6RojZBqOaMRB8DSX6cp.png","tagline":"Accelerator","urlname":"/program_page/eit-health-1","isisraeli":0,"investorid":"sWm2IpxMHP3nh0WwFLOxQbRb6CxTwcu2kBtWkvK2w8HuBe5heYRow2","fundingtype":"General","leadpartner":null,"investmentid":"KUdeUBS90RVNBRsCryV8WWmlbtO1q9QCIpu8Rn5XCFmKQeiiND9hY8","fundingsubtype":"General","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$dIzwIswG6RskoZFZuZopSgKuR43bBmTTgee6RojZBqOaMRB8DSX6cp.png","leadcaption":"","followupcaption":""}],"eventvisibility":"Public","amountvisibility":null,"fundingvisibility":"Public","fundingtypefundingtype":"Undisclosed Round","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":null,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"FWaCZyLFTMGCZhMWkFidOfNb8HIkTy76YFatVNpr7VAcNafFP3WCDt","date":"Dec 2018","amount":"$10M","source":"https://www.yozma.com/portfolio","eventtype":"FundingRoundEvent","investment":[{"name":"The Yozma Group","type":"Investor","amount":null,"hidden":false,"country":"Israel","fullurl":"/investor_page/yozma-group","logokey":"$wVMapdgnKlFiqgrIKRf9wjNDUkTpRoZlYd4H0PB4CxZ9ctDMydVRD4","tagline":null,"urlname":"/investor_page/yozma-group","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgKnapokKDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"OCLnq0Ka9oKZSSKOZz5GrkOf7RZ6uYFJZrEyZcHtQ65f8Xricny7g5","fundingsubtype":"VC and Private Equity","investorislead":1,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$wVMapdgnKlFiqgrIKRf9wjNDUkTpRoZlYd4H0PB4CxZ9ctDMydVRD4","leadcaption":"Lead ","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"Seed","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":10000000,"capitalraised":"Undisclosed","valuation":"Undisclosed"}],"nonequityfunding":[{"id":"mRsYpjKAEScOm9iEISSUC6ttu040agSa1aXCCPmlNnr4jgk2VXr2zw","date":"Aug 2025","amount":"$350K","source":"","eventtype":"GrantEvent","granttype":0,"investment":[{"name":null,"type":null,"amount":null,"hidden":false,"country":"Israel","fullurl":null,"logokey":null,"tagline":null,"urlname":null,"isisraeli":null,"investorid":null,"fundingtype":"Angel","leadpartner":null,"investmentid":"8CsbpOCC0TMnbyjXLrfD3Sm1MWO6oYd8dhnNk45OqsckPAnbDNdkNZ","fundingsubtype":null,"investorislead":0,"amountvisibility":"Public","isextensionround":null,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"/assets/empty-state.svg","investmentVisibilityClassName":"","investmentVisibilityTooltip":"","leadcaption":"","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":null,"isjointventuregrant":0,"style":"","hiddenCompanyTooltip":"","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","sectionname":"Non-Equity Funding","isgrant":true,"isicoevent":false,"amountnumber":350000,"capitalraised":"Undisclosed","valuation":"Undisclosed"}],"merger_acquisitions":[],"others":[]}}